Revolutionize Care With Pioneering Bispecific Antibody Therapy
Red blood cells in the blood stream stock image - erythrocytes, leukocytes

Pioneering the Future of Medicine with Breakthrough NTIG Drug Development

Complete the Form to Access Article

Revolutionize Care with Pioneering Bispecific Antibody Therapy

Authors: Select Science | Last updated: December 2023

Overview

In this exclusive interview with Jiseon Kim, Senior Researcher at ProGen, we explore the groundbreaking research on the development of a novel antibody-based drug for the treatment of cancer and autoimmune diseases. Through the utilization of Neo Tri-ImmunoGlobulin (NTIG), a fusion protein platform designed to enable multi-targeting and long-term drug persistence, Kim’s team is revolutionizing the field of drug discovery and antibody-based medicine. 

  • Document type: Article
  • Page count: 5
  • Read time: 8 minutes

Complete the Form to Access Article

Key Takeaways

  • Discover ProGen's NTIG technology for next-gen cancer and autoimmune disease treatments
  • Learn how NTIG's multi-targeting approach surpasses conventional drug therapies
  • Understand the challenges and importance of precise binding affinity in drug development
  • Explore the role of the Octet® R8 BLI System in advancing antibody medicine
  • Get to know how the mechanical pipette Tacta® facilitates and streamlines research effort and the Safe Cone Filter reduces the contamination of the pipette.

This Resource is Designed for:

  • Oncologists
  • Immunologists
  • Researchers in the Field of Drug Discovery and Development

Applications Supported:

  • Bispecific Antibody Therapy 
  • Drug Discovery and Development 
  • Cancer and Autoimmune Disease Treatment
  • Biomedical Research
  • Pipetting
  • Mechanical Pipettes

Resource Preview

Complete the Form to Access Article

icon-shopping-cart
Ready to Buy?